<code id='0315B3C735'></code><style id='0315B3C735'></style>
    • <acronym id='0315B3C735'></acronym>
      <center id='0315B3C735'><center id='0315B3C735'><tfoot id='0315B3C735'></tfoot></center><abbr id='0315B3C735'><dir id='0315B3C735'><tfoot id='0315B3C735'></tfoot><noframes id='0315B3C735'>

    • <optgroup id='0315B3C735'><strike id='0315B3C735'><sup id='0315B3C735'></sup></strike><code id='0315B3C735'></code></optgroup>
        1. <b id='0315B3C735'><label id='0315B3C735'><select id='0315B3C735'><dt id='0315B3C735'><span id='0315B3C735'></span></dt></select></label></b><u id='0315B3C735'></u>
          <i id='0315B3C735'><strike id='0315B3C735'><tt id='0315B3C735'><pre id='0315B3C735'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:5
          Stock Market
          APStock

          Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

          When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

          advertisement

          Read on for brief explanations of what we’re watching for from each company.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Top private equity targets in 2023: cardiology, clinical trials, lasers
          Top private equity targets in 2023: cardiology, clinical trials, lasers

          AdobeBysomemeasures,privateequityinvestmentlaggedin2023,ayearmarkedbygrowingdistressandhigh-profiled

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          A single Democrat is willing to weaken Medicare negotiation power

          U.S.RepresentativeDonDavis(D-N.C.)WikimediaCommonsWASHINGTON—TwoRepublicanlawmakerswhointroducedlegi